It's not that rare to see stocks in the volatile biotech industry that quadruple (or more) in value over a relatively short period. That's what has happened to Moderna (NASDAQ:MRNA) and Iovance Biotherapeutics (NASDAQ:IOVA) this year. Shares of the former are up 570%, while the latter has gained 433%. The question for investors is whether these companies are still worth investing in after their impressive runs this year. My view is that they aren't. Here is why. Image source: Getty Images. Moderna achieved a significant milestone this year. The company reported positive Phase 3 results for intismeran autogene in certain patients with melanoma. Intismeran autogene is an investigational personalized cancer vaccine, a category of products designed to target mutations specific to patients' own tumor cells.
CryptoAlerta — análise de criptomoedas e mercado em tempo real